China Market Entry Strategy Case Study
Curation of partnering candidates and detailed revenue forecast to support licensing initiatives
The Situation
- A U.S. biotech company seeks to understand China ovarian cancer market situation and to assess potential for a novel therapy among four patient segments in later line treatment
The Ask
- Develop a list of potential partners and prioritize them
- Detailed forecast of market opportunities for the four targeted patient segments
- An overview of China healthcare landscape, including pricing, reimbursement, and local competition
The Actions
1
Partner Curation
- 40+ China-based companies were analyzed for their potential as partners for the China market rights for the asset
- We analyzed and recommended top ten partnering candidates
2
Opportunity Assessment
- We outlined the pricing and reimbursement environment for oncology drugs
- We mapped out detailed clinical pathway for two main types of patients based on treatment guidelines and in-depth interviews with Chinese KOLs
- We developed treatment paradigm with patient volume estimations
- We constructed a quantitative model based on current treatment paradigm and estimated market opportunities for the novel therapy in each patient segment and line of treatment
The Impact
Assisted the client in understanding the unique market landscape in China and potential hurdles
Developed fact-based revenue forecast to support term sheet development
Curated potential partners for BD&L initiatives
Representative Deliverables
Potential Partner Curation
Chinese Insurance System
OC Treatment Paradigm
Revenue Forecast
